Yuhan Corporation has signed an active pharmaceutical ingredient (API) supply contract worth approximately KRW 131.1 billion with a global pharmaceutical company. According to the Financial Supervisory Service’s electronic disclosure system (DART), the contract value is KRW 131,074,406,400, or USD 95,424,000. This represents approximately 6.0% of Yuhan Corporation’s consolidated revenue for 2025.

Key Change

The key point is that Yuhan Corporation disclosed an API supply contract with a global pharmaceutical company on September 1, 2026. The contract is worth approximately KRW 131.074 billion, a material amount when compared with the company’s recent revenue.

Yuhan Corporation public-domain image
Yuhan Corporation · Wikimedia Commons · Public domain
The contract value is KRW 131,074,406,400, approximately 6.0% of the company’s latest revenue.

Current Status

The contract period runs from September 1, 2026, through May 31, 2028. However, the contract end date may be changed by mutual agreement between the two companies.

Some information has not been disclosed. The counterparty’s company name and specific contract details were withheld at the counterparty’s request and for business confidentiality reasons. Reports state that the disclosure deferment period for the relevant confidential information runs through May 31, 2028.

Impact

The full contract value cannot be assumed to be immediately reflected in Yuhan Corporation’s 2026 results. Revenue from a supply contract is recognized as products are supplied over the contract period. Therefore, the disclosure shows the scale of the contract, while the timing of actual revenue recognition must be considered separately based on the progress of deliveries.

There is no official confirmation that this contract is directly related to a specific medicine or the supply of raw materials for Leclaza. Accordingly, the product supplied and the counterparty cannot be identified based solely on the publicly available information.

Next Checkpoints

The following points will be relevant for future updates:

  1. The contract period through May 31, 2028, and any change to the end date
  2. The timing of revenue recognition as supplies are delivered
  3. The counterparty and specific contract details that may be disclosed after the disclosure deferment period